• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Is direct acting antiviral therapy for hepatitis c viral infection associated with increased risk of hepatocellular carcinoma before or after liver transplantation?丙型肝炎病毒感染的直接抗病毒治疗与肝移植前后肝细胞癌风险增加有关吗？
Hepatobiliary Surg Nutr. 2019 Oct;8(5):563-565. doi: 10.21037/hbsn.2019.05.10.
2
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
3
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
4
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联：是否存在联系？
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
5
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
6
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
7
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
8
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.美国胃肠病学会协会临床实践更新-专家评论：慢性丙型肝炎感染抗病毒治疗后获得持续病毒学应答患者的治疗。
Gastroenterology. 2017 May;152(6):1578-1587. doi: 10.1053/j.gastro.2017.03.018. Epub 2017 Mar 23.
9
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.AGA 临床实践更新：口服直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的相互作用：专家综述。
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
10
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.美国退伍军人肝细胞癌患者队列中丙型肝炎抗病毒治疗的有效性。
J Hepatol. 2017 Jul;67(1):32-39. doi: 10.1016/j.jhep.2017.02.027. Epub 2017 Mar 4.

本文引用的文献

1
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?直接作用抗病毒治疗的肝移植患者肝细胞癌复发风险是否增加？
Hepatol Int. 2019 Mar;13(2):190-198. doi: 10.1007/s12072-019-09930-x. Epub 2019 Jan 24.
2
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.直接作用抗病毒治疗与多中心北美队列研究中肝细胞癌的复发无关。
Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.
3
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.丙型肝炎抗病毒治疗后肝细胞癌风险预测模型的建立。
J Hepatol. 2018 Nov;69(5):1088-1098. doi: 10.1016/j.jhep.2018.07.024. Epub 2018 Aug 21.
4
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.慢性丙型肝炎合并失代偿性肝硬化患者直接抗病毒治疗后结局。
J Hepatol. 2016 Oct;65(4):741-747. doi: 10.1016/j.jhep.2016.06.019. Epub 2016 Jul 5.
5
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
6
Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.接受无干扰素直接抗病毒治疗后获得持续病毒学应答的肝硬化患者中肝细胞癌意外高发。
J Hepatol. 2016 Oct;65(4):856-858. doi: 10.1016/j.jhep.2016.06.009. Epub 2016 Jun 16.
7
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
8
Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.在丙型肝炎病毒（HCV）无干扰素治疗时代，患者背景的变化可能会增加持续病毒学应答（SVR）后肝细胞癌（HCC）的发生率。
Hepatology. 2016 Nov;64(5):1818-1819. doi: 10.1002/hep.28632. Epub 2016 Jun 7.
9
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
10
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.

Is direct acting antiviral therapy for hepatitis c viral infection associated with increased risk of hepatocellular carcinoma before or after liver transplantation?

作者信息

Jain Ashokkumar, Miller Danielle, Kadry Zakiyah

机构信息

Department of Surgery, Division of Transplant, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA.

出版信息

Hepatobiliary Surg Nutr. 2019 Oct;8(5):563-565. doi: 10.21037/hbsn.2019.05.10.

DOI:10.21037/hbsn.2019.05.10
PMID:31673560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6791969/
Abstract
摘要